Compare JQC & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JQC | AKBA |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 753.9M | 729.1M |
| IPO Year | N/A | 2014 |
| Metric | JQC | AKBA |
|---|---|---|
| Price | $4.84 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 842.3K | ★ 3.3M |
| Earning Date | 01-01-0001 | 05-27-2026 |
| Dividend Yield | ★ 11.13% | N/A |
| EPS Growth | N/A | ★ 93.94 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.84 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.60 | $1.14 |
| 52 Week High | $5.59 | $4.08 |
| Indicator | JQC | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 31.79 | 43.18 |
| Support Level | N/A | $1.14 |
| Resistance Level | $5.16 | $1.57 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 15.71 | 22.83 |
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.